Return to search

PE-backed VLR acquires Comprehensive Clinical Trials

VitaLink Research, which is backed by Great Point Partners, has acquired West Palm Beach, FL-based Comprehensive Clinical Trials, a provider of clinical trials with a therapeutic focus in women’s health. No financial terms were disclosed.


GREENWICH, CT and GREENVILLE, SC –VitaLink Research (“VLR”) today announced that it has acquired West Palm Beach, FL-based Comprehensive Clinical Trials (“CCT”). CCT focuses on providing Phase II – IV clinical trials with a therapeutic focus in women’s health.

The addition of CCT enables VitaLink Research to provide high-quality clinical research to a greater number of patients throughout the Southeast.

“The partnership with Comprehensive Clinical Trials is a critical milestone in the company’s expansion into the growing field of women’s health,” said Nick Wright, CEO of VitaLink Research. “The addition of CCT enables us to partner with the fantastic team that Dr. Ackerman has built throughout his distinguished career as a physician and Principal Investigator.

Additionally, I look forward to working with Dr. Ackerman to strategically grow our women’s health clinical research capabilities in existing VitaLink Research sites to increase the number of patients who can participate in these important research studies. Dr. Ackerman’s expertise in clinical research is world renowned and he will continue to lead the CCT business.”

“I am excited to partner with the entire VitaLink Research team to further grow our combined business over the coming years,” said Dr. Ronald Ackerman, Founder of CCT. “The strong infrastructure that VitaLink has established will enable CCT to focus exclusively on clinical research and expanding our women’s health expertise throughout the VitaLink network.”

About VitaLink Research
VitaLink Research (“VLR”) was founded in 2004 and has since become a leading dedicated clinical research site business with 13 locations in the U.S. Headquartered in Greenville, SC, VLR’s model is an effective method of research operations and management that consistently exceeds sponsor and FDA expectations during all quality audits while consistently ranking in the top 10% in global enrollment. The clustering of sites provides the opportunity for inter-site cross training, idea exchange, and standardization of operating procedures. With over ten years of shared experiences the company has developed best practices which continue to be the foundations of its successful U.S. operations. Learn more at

About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1 billion of equity capital under management and 28 professionals, investing in the United States, Canada and Western Europe. GPP is currently making new private equity investments from GPP III, a $306 million fund. Great Point Partners manages capital in private (GPP I, $156 million, GPP II, $215 million, and GPP III, $306 million) and public (BioMedical Value Fund, approximately $1.3 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. For further information, please contact Great Point Partners at 203-971-3300 or